Salud financiera de hoja de balance de Human Metabolome Technologies

Salud financiera controles de criterios 5/6

Human Metabolome Technologies tiene un patrimonio de accionistas total de ¥1.8B y una deuda total de ¥200.0M, lo que sitúa su ratio deuda-patrimonio en 11%. Sus activos y pasivos totales son ¥2.3B y ¥480.0M respectivamente. El BAIT de Human Metabolome Technologies es de ¥245.0M, por lo que su ratio de cobertura de intereses es de 122.5. Tiene efectivo e inversiones a corto plazo que ascienden a ¥1.5B.

Información clave

11.0%

Ratio deuda-patrimonio

JP¥200.00m

Deuda

Ratio de cobertura de intereses	122.5x
Efectivo	JP¥1.46b
Patrimonio	JP¥1.81b
Total pasivo	JP¥480.00m
Activos totales	JP¥2.29b

Actualizaciones recientes sobre salud financiera

Recent updates

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 03

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Aug 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Jun 07

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

May 22

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Apr 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Mar 23

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Feb 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥1.8B) de 6090 superan a sus pasivos a corto plazo (¥458.0M).

Pasivo a largo plazo: Los activos a corto plazo de 6090 (¥1.8B) superan a sus pasivos a largo plazo (¥22.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 6090 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 6090 ha crecido de 0% a 11% en los últimos 5 años.

Cobertura de la deuda: La deuda de 6090 está bien cubierta por el flujo de caja operativo (118%).

Cobertura de intereses: Los pagos de intereses de la deuda de 6090 están bien cubiertos por el BAIT (122.5x cobertura).

Salud financiera de hoja de balance de Human Metabolome Technologies

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Recent updates

Less than half of directors are independent

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Investor sentiment deteriorates as stock falls 21%

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥15.00 per share

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)

Dividend of JP¥15.00 announced

Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024

First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)

Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023

New major risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023

Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)

Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Insufficient new directors

Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)

Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)

New 90-day high: JP¥999

Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021

New 90-day low: JP¥741

New 90-day low: JP¥860

Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020

Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera